Heteroaromatic compounds and their use as dopamine D1 ligands

US9527843B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Jennifer Elizabeth Davoren · Cambridge, US
• Amy Beth Dounay · Colorado Springs, US
• Ivan Viktorovich Efremov · Sharon, US
• David Lawrence Firman Gray · Groton, US
• Scot Richard Mente · Arlington, US
• Steven Victor O'Neil · East Lyme, US
• Bruce N. Rogers · Belmont, US
• Chakrapani Subramanyam · South Glastonbury, US
• Lei Zhang · Beijing, CN

Key dates

• Filing date: Aug 6, 2015
• Grant date: Dec 27, 2016
• Expiry date: Aug 6, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides, in part, compounds of Formula I:and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.